Company Overview and News

KLCI remains in the red in tandem with regional markets

2018-10-09 theedgemarkets
KUALA LUMPUR (Oct 9): The FBM KLCI remained in negative zone at mid-morning today, in tandem with regional markets that were also mostly in the red.
SPMXF UPBMF 7036 1163 7087 ORHLF 5168 2089 5256 9334 4006 KLKBY 2445 SPMXY 5819 HRGHY

KLCI reverses loss, edges up in line with region

2018-08-01 theedgemarkets
KUALA LUMPUR (Aug 1): The FBM KLCI reversed its earlier loss and climbed into positive territory at the midday break today, tracking gains at the regional markets.
HLFBF 7036 7374 5134 GMALY 2852 5029 5347 0035 4715 TNABY 5208 PNAGF 1929 GMALF 1082 ORHLF 6033 7123 5436 4006 PNADF 0026 5819 TNABF

KLCI pares loss, remains above 1,760-level

2018-07-27 theedgemarkets
KUALA LUMPUR (July 27): The FBM KLCI dipped 0.25% at midday break but pared its losses to stay above the 1,760-point level.
9385 4065 7113 TPGVF BATS 4162 5246 5202 ORHLF 7277 7123 4006 TGLVY 2739 2836 GEBHF 3719

KLCI edges up as sentiment perks up on Wall St rally

2018-07-26 theedgemarkets
KUALA LUMPUR (July 26): The FBM KLCI rose in early trade, tracking gains the regional markets following the overnight rally at Wall Street.
HLFBF 4006 7293 3867 5819 1082 MYPRY ORHLF 5014

KLCI reverses gains, falls 0.63% as regional markets slip

2018-07-03 theedgemarkets
KUALA LUMPUR (July 3): The FBM KLCI reversed its earlier gains and fell 0.63% at mid-morning today, as Asian markets slipped.
4006 KLKBY 5139 2445 0900 6888 7036 5681 AXXTF 1163 ORHLF 7055

Oriental plans to operate its new oil mill in Indonesia next year

Positive contribution: Oriental says the oil mill will meet the projected output of fresh fruit bunch from the group’s young trees in south Sumatra from 2020 to 2022
4006 ORHLF

Bumpy road ahead

PETALING JAYA: Malaysian vehicle sales could fall for a third year in a row in 2018, weighed down by weaker sales, poor consumer sentiment, stringent loan approval rates and generally unfavourable market conditions.
4006 4588 4405 ORHLF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...